getting to the heart of the matter

Novel therapeutics and diagnostics targeting the multi-factorial root causes of CVD

CVD and

the Arterez approach

Cardiovascular disease (CVD), particularly coronary heart disease (CHD) remains the No. 1 disease killer and is rising in the  world.  By 2030, 23.6 million people are predicted to die from CVD.  In the U.S., 42% of all deaths annually are a direct result of CVD; one person dies every 33 seconds from heart disease and it is the leading cause of death for all Americans age 35 and older.  

While current symptom-targeted drugs are at best palliative, Arterez has developed a novel 3x compound, synthetic oral therapy and companion diagnostic panel targeting the multi-factorial root causes of CVD.   

"Historical development of antibiotics targeting microorganisms led to a cure of infectious disease. An equivalent approach is to target the endothelial glycocalyx to cure CVD by an anti-embolic™ mechanism."

Dr. Joe Tunac

Offerings and IP Summary

Primary Offerings

IP Matter Description

 

Embotricin

A rationally synthesized,  triple compound,  oral therapy with unique mechanisms of action targeting the root causes of CVD proven to prevent and reverse arterial plaques, the hallmark of CVD.

 

GlycoCardia™

A therapeutic aide and series of diagnostic panels  that provide specific information on the associated pathology and risk factors of  CVD diseases and stages based on our Glycalyx Detritus Fingerprinttechnology.

Drug Treatment and Biomarker Panel Targeted
to Diseases Due to Multifactorial Ontology of
Glycocalyx Disruption.


Biomarkers of Vascular Disease.


Methods and Compositions for Reversing
Disruption of the Glycocalyx, Inflammation and
Oxidative Damage.


(Draft - to be published Q2, 2020) Natural Animal Model for CVD and Inflammation.

Recent News

In The News

 

248.931.9091

  • YouTube

Find us on Youtube

Get In Touch

© 2020  All Copyrights Reserved, Arterez, LLC